GH Research PLC

GH Research Ireland Limited is a clinical-stage biopharmaceutical company focused on developing treatments for depression. The company's primary objective is to transform patients' lives by creating a practice-changing treatment for depression, with an initial focus on treatment-resistant depression (TRD). Its portfolio includes two proprietary mebufotenin therapies: GH001, an inhalable product candidate, and GH002, an intravenous product candidate. While GH001 currently uses a third-party vaporization device, GH Research Ireland Limited is developing its own proprietary aerosol delivery device, which is undergoing clinical investigation in Europe. The company has completed two Phase 1 healthy volunteer clinical trials for GH001 (GH001-HV-101 and GH001-HV-103). These trials observed that GH001, when administered via inhalation, was well tolerated at the single dose levels investigated and within an individualized dosing regimen (IDR) involving intra-subject dose escalation within a single day. Since January 1, 2023, the company's principal expenditures have been research and development expenses. GH Research Ireland Limited was originally incorporated in Ireland on October 16, 2018, as GH Research Limited, and re-registered as GH Research Ireland Limited on March 29, 2021. Its principal place of business is in Dublin 2, D02 RY95, Ireland.